Navigation Links
Biosimilars Market Expected to Soar
Date:2/14/2013

LONDON, Feb. 14, 2013 /PRNewswire/ -- Top representatives from the healthcare industry are confirmed to attend the 2nd Biosimilars Congregation which will take place in London on the 19th and 20th of February 2013. Ranjith Gopinathan , Frost & Sullivan Program Manager for Life Sciences, Europe Practice, is set to participate to the event's Keynote Panel Discussion focusing on challenges and opportunities in the global biosimilars market.

"Experience in biosimilars development, manufacturing and commercialisation in regulated markets such as Europe and the US is limited. Furthermore, reluctance from some physicians and patients to adopt biosimilars due to perceived efficacy and safety issues could have an adverse impact on market penetration. Such uncertainties, in addition to the complex regulatory pathway, compound the risks for biosimilars manufacturers," says Ranjith Gopinathan , Frost & Sullivan Program Manager for Life Sciences, Frost & Sullivan.

Initially, manufacturers of biosimilars will focus on the 3 protein classes of erythropoiein and human growth hormone due to their recent patent expiry. In the long run, insulin, interferon and more complex proteins like monoclonal antibodies are likely to emerge.  However, some companies may concentrate on certain therapeutic classes depending on their capabilities and strategic fit.

Europe has the highest number of biosimilars approvals in the regulated market and will continue to increase in the near future. Further patent expiries of biologics will likely increase the number of approved biosimilars and players in the market and thereby will bring in a greater number of products that will increase the market size. Biosimilars are currently priced at about 20-30% below the original product price.

The 2nd Biosimilars Congregation 2013, which is organised by Virtue Insight, will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof, who will address the industry key issues - ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects. The event will take place in London, UK, on the 19th and 20th of February.

For more information please click on the following link or contact fen.castro@virtueinsight.com - http://www.virtueinsight.com/pharma/2nd-Biosimilars-Congregation-2013/

About Virtue Insight
Virtue Insight equips business professionals around the world with the latest in-depth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry. 

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion

Contact

Fen Castro
Head - Productions
Virtue Insight
P (India) + 0091 44 64998743; Mob + 91 9003 26 0693
P (UK) + 44 2033024659; Mob + 44 7424406352
E: fen.castro@virtueinsight.com
www.virtueinsight.com

Anna Zanchi
Corporate Communications – Europe
Frost & Sullivan
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
2. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
3. Biosimilars: Global Markets
4. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
5. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
6. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
7. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
8. New Product Launch: Are your Strategies for Emerging Healthcare and Life Sciences Markets Innovative and Structured?
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
11. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... , Feb. 16, 2017 UCHealth ( ... utilize LungDirect for pulmonary nodule patient management. In addition ... or a spot on the lung, UCHealth looks to ... manual data entry. Stephanie Brown, RN ... my nodule patients with an Excel spreadsheet, which was ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
Breaking Biology News(10 mins):